Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328049169> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W4328049169 endingPage "e492" @default.
- W4328049169 startingPage "e488" @default.
- W4328049169 abstract "Abstract Background Hyperglycemia is recognized as a common adverse event for patients receiving alpelisib but has been little studied outside of clinical trials. We report the frequency of alpelisib-associated hyperglycemia in a real-world setting and evaluate proposed risk factors. Patients and Methods We retrospectively identified patients with PIK3CA-mutated, hormone receptor-positive, metastatic breast cancer who initiated treatment with alpelisib plus fulvestrant between August 2019 and December 2021. Ordinal logistic regression evaluated 5 characteristics (diabetes, prediabetes, body mass index [BMI], age, and Asian ancestry) as independent risk factors for ALP-associated hyperglycemia grades 2-4. Risk of error from multiple hypothesis testing was controlled using the false discovery rate method. Results The study included n = 92 subjects, all but 1 female, mean age 59.9 (+11.9) years with 50% non-Hispanic White, 15% Hispanic/Latino, 13% Asian, 9% African/Black, and 13% other/unknown. In total 34% of patients had diabetes, 10% had pre-diabetes, and 56% had normoglycemia. Thirty-six percent were obese, 32% were overweight, 25% were normal weight, and 7% were lean. Frequency of grades 1-4 hyperglycemia in current subjects (64.1%) was similar to hyperglycemia reported in the SOLAR-1 trial (63.7%). Our subjects’ risk of grades 2-4 hyperglycemia was independently increased by pre-existing diabetes (Odds ratio 3.75, 95% CI, 1.40-10.01), pre-diabetes (6.22, 1.12-34.47), Asian ancestry (7.10, 1.75-28.84), and each unit of BMI above 20 (1.17, 1.07-1.28). Conclusion While receiving alpelisib, patients of Asian ancestry, as well as patients with pre-existing hyperglycemia and/or BMI above 20, should be closely monitored for hyperglycemia. The mechanism underlying the current association of alpelisib-associated hyperglycemia with Asian ancestry is independent of BMI and merits further study. The high incidence of hyperglycemia resulted in a change in practice to include consultation with a diabetes nurse educator or endocrinologist at the start of alpelisib." @default.
- W4328049169 created "2023-03-22" @default.
- W4328049169 creator A5004500382 @default.
- W4328049169 creator A5005344580 @default.
- W4328049169 creator A5005473474 @default.
- W4328049169 creator A5011540763 @default.
- W4328049169 creator A5013275278 @default.
- W4328049169 creator A5026465614 @default.
- W4328049169 creator A5036139011 @default.
- W4328049169 creator A5041448171 @default.
- W4328049169 creator A5046707505 @default.
- W4328049169 creator A5056788331 @default.
- W4328049169 creator A5064748883 @default.
- W4328049169 date "2023-03-21" @default.
- W4328049169 modified "2023-09-30" @default.
- W4328049169 title "Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer" @default.
- W4328049169 cites W1513833217 @default.
- W4328049169 cites W2053405913 @default.
- W4328049169 cites W2125687910 @default.
- W4328049169 cites W2333205054 @default.
- W4328049169 cites W2945564879 @default.
- W4328049169 cites W3025082211 @default.
- W4328049169 cites W3042783220 @default.
- W4328049169 cites W3109453522 @default.
- W4328049169 cites W3141372695 @default.
- W4328049169 cites W3204712500 @default.
- W4328049169 cites W4221041388 @default.
- W4328049169 doi "https://doi.org/10.1093/oncolo/oyad024" @default.
- W4328049169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36943382" @default.
- W4328049169 hasPublicationYear "2023" @default.
- W4328049169 type Work @default.
- W4328049169 citedByCount "1" @default.
- W4328049169 countsByYear W43280491692023 @default.
- W4328049169 crossrefType "journal-article" @default.
- W4328049169 hasAuthorship W4328049169A5004500382 @default.
- W4328049169 hasAuthorship W4328049169A5005344580 @default.
- W4328049169 hasAuthorship W4328049169A5005473474 @default.
- W4328049169 hasAuthorship W4328049169A5011540763 @default.
- W4328049169 hasAuthorship W4328049169A5013275278 @default.
- W4328049169 hasAuthorship W4328049169A5026465614 @default.
- W4328049169 hasAuthorship W4328049169A5036139011 @default.
- W4328049169 hasAuthorship W4328049169A5041448171 @default.
- W4328049169 hasAuthorship W4328049169A5046707505 @default.
- W4328049169 hasAuthorship W4328049169A5056788331 @default.
- W4328049169 hasAuthorship W4328049169A5064748883 @default.
- W4328049169 hasBestOaLocation W43280491691 @default.
- W4328049169 hasConcept C121608353 @default.
- W4328049169 hasConcept C126322002 @default.
- W4328049169 hasConcept C134018914 @default.
- W4328049169 hasConcept C156957248 @default.
- W4328049169 hasConcept C207103383 @default.
- W4328049169 hasConcept C2777180221 @default.
- W4328049169 hasConcept C2779668308 @default.
- W4328049169 hasConcept C2780221984 @default.
- W4328049169 hasConcept C2780482068 @default.
- W4328049169 hasConcept C2780586474 @default.
- W4328049169 hasConcept C44249647 @default.
- W4328049169 hasConcept C530470458 @default.
- W4328049169 hasConcept C555293320 @default.
- W4328049169 hasConcept C71924100 @default.
- W4328049169 hasConcept C84606932 @default.
- W4328049169 hasConceptScore W4328049169C121608353 @default.
- W4328049169 hasConceptScore W4328049169C126322002 @default.
- W4328049169 hasConceptScore W4328049169C134018914 @default.
- W4328049169 hasConceptScore W4328049169C156957248 @default.
- W4328049169 hasConceptScore W4328049169C207103383 @default.
- W4328049169 hasConceptScore W4328049169C2777180221 @default.
- W4328049169 hasConceptScore W4328049169C2779668308 @default.
- W4328049169 hasConceptScore W4328049169C2780221984 @default.
- W4328049169 hasConceptScore W4328049169C2780482068 @default.
- W4328049169 hasConceptScore W4328049169C2780586474 @default.
- W4328049169 hasConceptScore W4328049169C44249647 @default.
- W4328049169 hasConceptScore W4328049169C530470458 @default.
- W4328049169 hasConceptScore W4328049169C555293320 @default.
- W4328049169 hasConceptScore W4328049169C71924100 @default.
- W4328049169 hasConceptScore W4328049169C84606932 @default.
- W4328049169 hasIssue "7" @default.
- W4328049169 hasLocation W43280491691 @default.
- W4328049169 hasLocation W43280491692 @default.
- W4328049169 hasLocation W43280491693 @default.
- W4328049169 hasOpenAccess W4328049169 @default.
- W4328049169 hasPrimaryLocation W43280491691 @default.
- W4328049169 hasRelatedWork W2025944879 @default.
- W4328049169 hasRelatedWork W2047073111 @default.
- W4328049169 hasRelatedWork W2103858873 @default.
- W4328049169 hasRelatedWork W2161526655 @default.
- W4328049169 hasRelatedWork W2376558280 @default.
- W4328049169 hasRelatedWork W2401680319 @default.
- W4328049169 hasRelatedWork W2782707581 @default.
- W4328049169 hasRelatedWork W2990663937 @default.
- W4328049169 hasRelatedWork W3184879214 @default.
- W4328049169 hasRelatedWork W4220718597 @default.
- W4328049169 hasVolume "28" @default.
- W4328049169 isParatext "false" @default.
- W4328049169 isRetracted "false" @default.
- W4328049169 workType "article" @default.